Role of FAM3 gene family in tumor

Abstract

Liao Chengcheng, An Jiaxing, Tan Zhangxue, Wang Qian, Liu Jianguo. Role of FAM3 gene family in tumor[J]. Journal of International Oncology, 2020, 47(10): 611-614.

References31

[1]	Zhang X, Yang W, Wang J, et al. FAM3 gene family: a promising therapeutical target for NAFLD and type 2 diabetes[J]. Metabolism, 2018,81:71-82. DOI: 10.1016/j.metabol.2017.12.001. pmid:29221790
[2]	Tanasova M, Begoyan VV, Weselinski LJ. Targeting sugar uptake and metabolism for cancer identification and therapy: an overview[J]. Curr Top Med Chem, 2018,18(6):467-483. DOI: 10.2174/1568026618666180523110837. pmid:29788891
[3]	Cao Y. Adipocyte and lipid metabolism in cancer drug resistance[J]. J Clin Invest, 2019,129(8):3006-3017. DOI: 10.1172/JCI127201. pmid:31264969
[4]	Wang H, Yu F, Zhang Z, et al. Effects of circulating member B of the family with sequence similarity 3 on the risk of developing metabolic syndrome and its components:a 5-year prospective study[J]. J Diabetes Investig, 2018,9(4):782-788. DOI: 10.1111/jdi.12780. pmid:29178453
[5]	Xiang R, Chen J, Li S, et al. VSMC-specific deletion of FAM3A attenuated angⅡ-promoted hypertension and cardiovascular hypertrophy[J]. Circ Res, 2020, In press. DOI: 10.1161/CIRCRESAHA.119.315558. doi:10.1161/CIRCRESAHA.120.317045pmid:33107387
[6]	Xu W, Liang M, Zhang Y, et al. Endothelial FAM3A positively regulates post-ischaemic angiogenesis[J]. EBioMedicine, 2019,43:32-42. DOI: 10.1016/j.ebiom.2019.03.038. pmid:31000420
[7]	Chaudhury A, Hussey GS, Ray PS, et al. TGF-β-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translatio-nal induction of Dab2 and ILEI[J]. Nat Cell Biol, 2010,12(3):286-293. DOI: 10.1038/ncb2029. doi:10.1038/ncb2029pmid:20154680
[8]	Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma[J]. Gastroenterology, 2018,154(2):360-373. DOI: 10.1053/j.gastro.2017.08.023. pmid:28823862
[9]	Zhu YH, Zhang B, Li M, et al. Prognostic significance of FAM3C in esophageal squamous cell carcinoma[J]. Diagn Pathol, 2015,10:192. DOI: 10.1186/s13000-015-0424-8. doi:10.1186/s13000-015-0424-8
[10]	Jin LL, Zhang SJ, Lu GX, et al. miR-574-3p inhibits proliferation and invasion in esophageal cancer by targeting FAM3C and MAPK1[J]. Kaohsiung J Med Sci, 2020,36(5):318-327. DOI: 10.1002/kjm2.12176.
[11]	He SL, Wang WP, Yang YS, et al. FAM3B promotes progression of oesophageal carcinoma via regulating the AKT-MDM2-p53 signalling axis and the epithelial-mesenchymal transition[J]. J Cell Mol Med, 2019,23(2):1375-1385. DOI: 10.1111/jcmm14040.
[12]	Song WM, Lin X, Liao X, et al. Multiscale network analysis reveals molecular mechanisms and key regulators of the tumor microenvironment in gastric cancer[J]. Int J Cancer, 2020,146(5):1268-1280. DOI: 10.1002/ijc.32643. doi:10.1002/ijc.32643pmid:31463974
[13]	李海军, 王孟薇, 吴本俨, 等. FAM3B基因cDNA克隆及其在胃癌细胞系BGC-823的表达[J]. 中国药物与临床, 2007,7(12):896-898. DOI: 10.3969/j.issn.1671-2560.2007.12.002.
[14]	Shi M, Duan G, Nie S, et al. Elevated FAM3C promotes cell epithelial-mesenchymal transition and cell migration in gastric cancer[J]. Onco Targets Ther, 2018,11:8491-8505. DOI: 10.2147/OTT.S178455. doi:10.2147/OTT.S178455pmid:30584315
[15]	Ahmed M. Colon cancer: a clinician's perspective in 2019[J]. Gastroenterology Res, 2020,13(1):1-10. DOI: 10.14740/gr1239. pmid:32095167
[16]	Li Z, Mou H, Wang T, et al. A non-secretory form of FAM3B promotes invasion and metastasis of human colon cancer cells by upregulating Slug expression[J]. Cancer Lett, 2013,328(2):278-284. DOI: 10.1016/j.canlet.2012.09.026. doi:10.1016/j.canlet.2012.09.026pmid:23059759
[17]	万晓晨, 马小红, 程璐, 等. FAM3C蛋白与结肠癌临床病理相关性[J]. 肿瘤学杂志, 2017,23(5):413-416. DOI: 10.11735/j.issn.1671-170X.2017.05.B011.
[18]	Gao ZH, Lu C, Wang ZN, et al. ILEI: a novel marker for epithelial-mesenchymal transition and poor prognosis in colorectal cancer[J]. Histopathology, 2014,65(4):527-538. DOI: 10.1111/his.12435. pmid:24738665
[19]	Solmi R, De Sanctis P, Zucchini C, et al. Search for epithelial-specific mRNAs in peripheral blood of patients with colon cancer by RT-PCR[J]. INT J Oncol, 2004,25(4):1049-1056. pmid:15375555
[20]	Llach J, Carballal S, Moreira L. Familial pancreatic cancer: current perspectives[J]. Cancer Manag Res, 2020,12:743-758. DOI: 10.2147/CMAR.S172421. doi:10.2147/CMAR.S172421pmid:32099470
[21]	Gronborg M, Kristiansen TZ, Iwahori A, et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach[J]. Mol Cell Proteomics, 2006,5(1):157-171. DOI: 10.1074/mcp.M500178-MCP200.
[22]	Souza JJS, Machado MCC, Fortes MAHZ, et al. Cytokine-like FAM3D gene is associated to diabetes mellitus in pancreatic adenocarcinoma[J]. Pancreas, 2006,33(4):498. DOI: 10.1097/00006676-200611000-00208.
[23]	Holt JD, Gerayli F. Prostate cancer screening[J]. Prim Care, 2019,46(2):257-263. DOI: 10.1016/j.pop.2019.02.007.
[24]	Maciel-Silva P, Caldeira I, de Assis Santos I, et al. FAM3B/PANDER inhibits cell death and increases prostate tumor growth by modulating the expression of Bcl-2 and Bcl-XL cell survival genes[J]. BMC Cancer, 2018,18(1):90. DOI: 10.1186/s12885-017-3950-9. pmid:29357840
[25]	Sun Y, Jia X, Gao Q, et al. The ubiquitin ligase UBE4A inhibits prostate cancer progression by targeting interleukin-like EMT inducer (ILEI)[J]. IUBMB Life, 2017,69(1):16-21. DOI: 10.1002/iub.1585.
[26]	La Rosa GRM, Gattuso G, Pedullà E, et al. Association of oral dysbiosis with oral cancer development[J]. Oncol Lett, 2020,19(4):3045-3058. DOI: 10.3892/ol.2020.11441. doi:10.3892/ol.2020.11441pmid:32211076
[27]	Wu CC, Xiao Y, Li H, et al. Overexpression of FAM3C is associa-ted with poor prognosis in oral squamous cell carcinoma[J]. Pathol Res Pract, 2019,215(4):772-778. DOI: 10.1016/j.prp.2019.01.019.
[28]	迟毓婧, 李玫, 禹祎萌, 等. FAM3C通过激活Akt促进口腔鳞癌细胞活力[J]. 中国病理生理杂志, 2019,35(3):424-429. DOI: 10.3969/j.issn.1000-4718.2019.03.007.
[29]	De Cicco P, Catani MV, Gasperi V, et al. Nutrition and breast cancer: a literature review on prevention, treatment and recurrence[J]. Nutrients, 2019,11(7):1514. DOI: 10.3390/nu11071514.
[30]	Woosley AN, Dalton AC, Hussey GS, et al. TGFβ promotes breast cancer stem cell self-renewal through an ILEI/LIFR signaling axis[J]. Oncogene, 2019,38(20):3794-3811. DOI: 10.1038/s41388-019-0703-z. doi:10.1038/s41388-019-0703-zpmid:30692635
[31]	Yang W, Feng B, Meng Y, et al. FAM3C-YY1 axis is essential for TGFβ-promoted proliferation and migration of human breast cancer MDA-MB-231 cells via the activation of HSF1[J]. J Cell Mol Med, 2019,23(5):3464-3475. DOI: 10.1111/jcmm.14243. doi:10.1111/jcmm.14243pmid:30887707

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References31

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.